Osama E. Rahma

7.3k total citations · 2 hit papers
113 papers, 2.9k citations indexed

About

Osama E. Rahma is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Osama E. Rahma has authored 113 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Oncology, 22 papers in Immunology and 20 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Osama E. Rahma's work include Cancer Immunotherapy and Biomarkers (70 papers), Pancreatic and Hepatic Oncology Research (29 papers) and Colorectal Cancer Treatments and Studies (28 papers). Osama E. Rahma is often cited by papers focused on Cancer Immunotherapy and Biomarkers (70 papers), Pancreatic and Hepatic Oncology Research (29 papers) and Colorectal Cancer Treatments and Studies (28 papers). Osama E. Rahma collaborates with scholars based in United States, Switzerland and Canada. Osama E. Rahma's co-authors include F. Stephen Hodi, Patrick A. Ott, Shilpa Grover, Paul R. Kunk, Rawad Elias, Seth M. Steinberg, Craig L. Slingluff, Anita Giobbie‐Hurder, Tim F. Greten and Austin G. Duffy and has published in prestigious journals such as Cell, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Osama E. Rahma

109 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Intersection between Tumor Angiogenesis and Immune Suppression

2019 363 citations Osama E. Rahma, F. Stephen Hodi Clinical Cancer Research profile →
Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy

2020 307 citations Michael P. Manos, F. Stephen Hodi et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Osama E. Rahma United States	28	2.1k	1.0k	520	485	371	113	2.9k
Simon Pernot France	25	2.2k 1.0×	938 0.9×	1.1k 2.0×	759 1.6×	285 0.8×	99	3.5k
Timothy L. Frankel United States	28	1.5k 0.7×	733 0.7×	557 1.1×	663 1.4×	358 1.0×	81	2.6k
Stefan Diem Switzerland	17	2.2k 1.0×	625 0.6×	629 1.2×	294 0.6×	292 0.8×	31	2.6k
Rachel E. Sanborn United States	25	2.8k 1.3×	1.1k 1.1×	1.3k 2.5×	751 1.5×	192 0.5×	154	3.7k
Janice M. Mehnert United States	26	2.5k 1.2×	969 1.0×	776 1.5×	886 1.8×	527 1.4×	63	3.7k
Changping Wu China	25	1.3k 0.6×	619 0.6×	508 1.0×	673 1.4×	199 0.5×	58	2.4k
Austin G. Duffy United States	27	1.5k 0.7×	580 0.6×	749 1.4×	512 1.1×	589 1.6×	87	2.8k
Fabiana Tatangelo Italy	37	1.7k 0.8×	304 0.3×	534 1.0×	653 1.3×	370 1.0×	129	3.2k
Jung Yong Hong South Korea	25	1.2k 0.6×	301 0.3×	605 1.2×	509 1.0×	243 0.7×	194	2.3k
Αthanasios Kotsakis Greece	35	2.5k 1.2×	717 0.7×	1.3k 2.4×	1.0k 2.1×	331 0.9×	166	3.6k

Countries citing papers authored by Osama E. Rahma

Since Specialization

Citations

This map shows the geographic impact of Osama E. Rahma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Osama E. Rahma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Osama E. Rahma more than expected).

Fields of papers citing papers by Osama E. Rahma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Osama E. Rahma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Osama E. Rahma. The network helps show where Osama E. Rahma may publish in the future.

Co-authorship network of co-authors of Osama E. Rahma

This figure shows the co-authorship network connecting the top 25 collaborators of Osama E. Rahma. A scholar is included among the top collaborators of Osama E. Rahma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Osama E. Rahma. Osama E. Rahma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hall, William A., Jiahe Li, Y. Nancy You, et al.. (2023). Prospective Correlation of Magnetic Resonance Tumor Regression Grade With Pathologic Outcomes in Total Neoadjuvant Therapy for Rectal Adenocarcinoma. Journal of Clinical Oncology. 41(29). 4643–4651. 15 indexed citations

Katz, Matthew H. G., Gina R. Petroni, Todd W. Bauer, et al.. (2023). Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma. Journal for ImmunoTherapy of Cancer. 11(12). e007586–e007586. 18 indexed citations

Mulcahy, Mary F., Halla Nimeiri, Osama E. Rahma, et al.. (2023). Real-world outcome analysis of patients with advanced gastric and gastroesophageal adenocarcinoma with HER2-low expression treated with first-line therapy.. Journal of Clinical Oncology. 41(4_suppl). 326–326. 2 indexed citations

Li, Michael, Danny Wong, Alexander S. Vogel, et al.. (2021). Effect of corticosteroid dosing on outcomes in high‐grade immune checkpoint inhibitor hepatitis. Hepatology. 75(3). 531–540. 46 indexed citations

Cunningham‐Bussel, Amy, Jiaqi Wang, Lauren Prisco, et al.. (2021). Predictors of Rheumatic Immune‐Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer. Arthritis & Rheumatology. 74(3). 527–540. 29 indexed citations

Giobbie‐Hurder, Anita, Isaac A. Klein, Michael P. Manos, et al.. (2021). Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors. SHILAP Revista de lepidopterología. 4(2). 35–44. 8 indexed citations

Rahma, Osama E., Joshua E. Reuss, Anita Giobbie‐Hurder, et al.. (2020). Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors. Clinical Cancer Research. 27(2). 485–491. 3 indexed citations

Kumar, Vivek, Atul B. Shinagare, Helmut G. Rennke, et al.. (2020). The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature. The Oncologist. 25(6). 505–514. 104 indexed citations

Li, Michael, Jordan Sack, Osama E. Rahma, et al.. (2020). Outcomes after resumption of immune checkpoint inhibitor therapy after high‐grade immune‐mediated hepatitis. Cancer. 126(23). 5088–5097. 40 indexed citations

10.

Atieh, Jessica, Jordan Sack, Richard Thomas, et al.. (2020). Gastroparesis Following Immune Checkpoint Inhibitor Therapy: A Case Series. Digestive Diseases and Sciences. 66(6). 1974–1980. 7 indexed citations

11.

Seethapathy, Harish, Sophia Zhao, Ian A. Strohbehn, et al.. (2020). Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors. Kidney International Reports. 5(10). 1700–1705. 43 indexed citations

12.

Leaf, Rebecca Karp, Deepa Rangachari, James W. Mier, et al.. (2019). Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. American Journal of Hematology. 94(5). 563–574. 49 indexed citations

13.

Nabel, Christopher S., Mariano Severgnini, Yin P. Hung, et al.. (2019). Anti-PD-1 Immunotherapy-Induced Flare of a Known Underlying Relapsing Vasculitis Mimicking Recurrent Cancer. The Oncologist. 24(8). 1013–1021. 11 indexed citations

14.

Elias, Rawad, Anita Giobbie‐Hurder, Nadine J. McCleary, et al.. (2018). Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis. Journal for ImmunoTherapy of Cancer. 6(1). 26–26. 153 indexed citations

15.

Duffy, Austin G., Chi Ma, Susanna V. Ulahannan, et al.. (2017). Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma. Clinical Cancer Research. 23(16). 4633–4641. 68 indexed citations

16.

Obeid, Joseph M., Paul R. Kunk, Victor M. Zaydfudim, et al.. (2017). Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?. Cancer Immunology Immunotherapy. 67(2). 161–174. 20 indexed citations

17.

Rahma, Osama E.. (2015). A Case Report of a Poorly Differentiated Neuroendocrine Carcinoma Diagnosed in the Bone Marrow. Gastroenterology & Hepatology Open Access. 3(2). 1 indexed citations

18.

Rahma, Osama E., et al.. (2014). Is the “3+3” Dose-Escalation Phase I Clinical Trial Design Suitable for Therapeutic Cancer Vaccine Development? A Recommendation for Alternative Design. Clinical Cancer Research. 20(18). 4758–4767. 41 indexed citations

19.

Rahma, Osama E., Sarah Bernstein, Seth M. Steinberg, et al.. (2014). Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer. Journal of Translational Medicine. 12(1). 353–353. 26 indexed citations

20.

Rahma, Osama E., Ramy Ibrahim, Antoun Toubaji, et al.. (2010). A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma. Journal of Translational Medicine. 8(1). 8–8. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact